173 related articles for article (PubMed ID: 37604934)
1. HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors.
Takeuchi M; Meguro A; Nakamura J; Chikagawa R; Osada R; Shibuya E; Hasumi Y; Yamada N; Ishihara M; Mizuki N
Sci Rep; 2023 Aug; 13(1):13580. PubMed ID: 37604934
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04.
Amagai R; Fujimura T; Yamazaki E; Takahashi M; Tamabuchi E; Kambayashi Y; Hashimoto A; Hashimoto K; Asano Y
J Dermatol; 2024 Jun; 51(6):854-857. PubMed ID: 38111371
[TBL] [Abstract][Full Text] [Related]
3. A shared HLA-DRB1 epitope in the DR beta first domain is associated with Vogt-Koyanagi-Harada syndrome in Indian patients.
Tiercy JM; Rathinam SR; Gex-Fabry M; Baglivo E
Mol Vis; 2010 Mar; 16():353-8. PubMed ID: 20216938
[TBL] [Abstract][Full Text] [Related]
4. HLA-DRB1 among patients with Vogt-Koyanagi-Harada disease in Saudi Arabia.
Iqniebi A; Gaafar A; Sheereen A; Al-Suliman A; Mohamed G; Al-Hussein K; Tabbara KF
Mol Vis; 2009 Sep; 15():1876-80. PubMed ID: 19756183
[TBL] [Abstract][Full Text] [Related]
5.
Anukul N; Pathanapitoon K; Leetrakool N; Guntiya T; Wita R; Palacajornsuk P; Klangsinsirikul P
Ocul Immunol Inflamm; 2021 Feb; 29(2):260-263. PubMed ID: 32965138
[TBL] [Abstract][Full Text] [Related]
6. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.
Fujimura T; Kambayashi Y; Tanita K; Sato Y; Hidaka T; Otsuka A; Tanaka H; Furudate S; Hashimoto A; Aiba S
J Dermatol; 2018 Jun; 45(6):735-737. PubMed ID: 29488243
[TBL] [Abstract][Full Text] [Related]
7. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report.
Kikuchi R; Kawagoe T; Hotta K
BMC Ophthalmol; 2020 Jun; 20(1):252. PubMed ID: 32580711
[TBL] [Abstract][Full Text] [Related]
8. Association of HLA-DR4/HLA-DRB1*04 with Vogt-Koyanagi-Harada disease: a systematic review and meta-analysis.
Shi T; Lv W; Zhang L; Chen J; Chen H
Sci Rep; 2014 Nov; 4():6887. PubMed ID: 25382027
[TBL] [Abstract][Full Text] [Related]
9. Visual outcomes and choroidal thickness associated with human leukocyte antigen DRB1*04 in unclassifiable uveitis in Japanese patients.
Misawa N; Tagami M; Sakai A; Kohno T; Honda S
BMC Ophthalmol; 2021 Dec; 21(1):457. PubMed ID: 34963463
[TBL] [Abstract][Full Text] [Related]
10. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis.
Damico FM; Cunha-Neto E; Goldberg AC; Iwai LK; Marin ML; Hammer J; Kalil J; Yamamoto JH
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2465-71. PubMed ID: 15980237
[TBL] [Abstract][Full Text] [Related]
11. Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.
Bricout M; Petre A; Amini-Adle M; Bezza W; Seve P; Kodjikian L; Dalle S; Thomas L
J Immunother; 2017; 40(2):77-82. PubMed ID: 28166182
[TBL] [Abstract][Full Text] [Related]
12. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
Madoe A; Schauwvlieghe PP; Jacob J
Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
[TBL] [Abstract][Full Text] [Related]
13. Correlation between visual acuity and human leukocyte antigen DRB1*04 in patients with Vogt-Koyanagi-Harada disease.
Misawa N; Tagami M; Kohno T; Honda S
BMC Ophthalmol; 2019 Nov; 19(1):214. PubMed ID: 31699055
[TBL] [Abstract][Full Text] [Related]
14. Vogt-Koyanagi-Harada syndrome in patients of Vietnamese ancestry.
Riddington L; Hall AJ; Tait B; Nicholson I; Varney M
Aust N Z J Ophthalmol; 1996 May; 24(2):147-9. PubMed ID: 9199747
[TBL] [Abstract][Full Text] [Related]
15. Major histocompatibility complex and strong human leukocyte antigen-DRB1 and gender association with Vogt-Koyanagi-Harada syndrome in Mexican Mestizos.
Aláez C; Flores-A H; Concha del Río LE; Munguía A; Rodríguez A; García D; Arellanes L; Gorodezky C
Hum Immunol; 2011 Dec; 72(12):1198-203. PubMed ID: 21964432
[TBL] [Abstract][Full Text] [Related]
16. [Association of HLA-DRB genes with Vogt-Koyanagi-Harada syndrome in a Chinese Han population].
Zhang M; Qiu C; Hu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):36-40. PubMed ID: 12903490
[TBL] [Abstract][Full Text] [Related]
17. HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410.
Shindo Y; Inoko H; Yamamoto T; Ohno S
Br J Ophthalmol; 1994 Mar; 78(3):223-6. PubMed ID: 7908535
[TBL] [Abstract][Full Text] [Related]
18. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens.
Sugita S; Takase H; Taguchi C; Imai Y; Kamoi K; Kawaguchi T; Sugamoto Y; Futagami Y; Itoh K; Mochizuki M
Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2547-54. PubMed ID: 16723469
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of Vogt-Koyanagi-Harada disease in a French cohort: ethnicity, systemic manifestations, and HLA genotype data.
Abad S; Monnet D; Caillat-Zucman S; Mrejen S; Blanche P; Chalumeau M; Mouthon L; Dhote R; Brézin AP
Ocul Immunol Inflamm; 2008; 16(1):3-8. PubMed ID: 18379934
[TBL] [Abstract][Full Text] [Related]
20. HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt-Koyanagi-Harada disease.
Goldberg AC; Yamamoto JH; Chiarella JM; Marin ML; Sibinelli M; Neufeld R; Hirata CE; Olivalves E; Kalil J
Hum Immunol; 1998 Mar; 59(3):183-8. PubMed ID: 9548078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
